GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (FRA:EX9) » Definitions » Unpaid Loss & Loss Reserve

Exelixis (FRA:EX9) Unpaid Loss & Loss Reserve


View and export this data going back to 2000. Start your Free Trial

What is Exelixis Unpaid Loss & Loss Reserve?

Unpaid Loss & Loss Reserve only applies to insurance companies.


Exelixis (FRA:EX9) Business Description

Industry
Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.